Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
CAMBRIDGE, Mass., April 27, 2018 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will webcast presentations from its Investor Day, including first quarter financial results, on Friday, May 4, 2018 at 8:00 a.m. ET in New York.
Presentations will be given by members of Agios' leadership team and external speakers including:
- David Schenkein, M.D., Chief Executive Officer
- Scott Biller, Ph.D., Chief Scientific Officer
- Chris Bowden, M.D., Chief Medical Officer
- Andrew Hirsch, Chief Financial Officer and Head of Corporate Development
- Steve Hoerter, Chief Commercial Officer
- Darrin Miles, Vice President, IDH Program Management
- Susan Pandya, M.D., Senior Medical Director, Clinical Development
- Kevin Marks, Ph.D., Senior Director, Head of Cancer Biology
- Maeve Lowery, M.B., B.Ch., B.A.O, Trinity College Dublin
A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The presentations are scheduled to begin at 8:00 a.m. ET and conclude at 12:00 p.m. ET. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Investors:
Renee Leck, 617-649-8299
Senior Manager, Investor Relations
[email protected]
Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
[email protected]
